The organisation works on accelerating development and delivery of affordable diagnostic tests for poverty-related diseases.

Daclatasvir, discovered and developed by Bristol-Myer Squibb, is the first-in-class NS5A inhibitor used in combination with Sofosbuvir to t...

Biotechnology major Biocon launches advanced novel therapy for the treatment of Hepatitis C at a fraction of the global cost.

Last year, Strides had entered into a licensing agreement with Gilead Sciences to bring Hepatitis C cure to 91 developing countries.

Cipla has launched generic tablets used for treating of hepatitis C under the brand name 'Hepcvir-L' costing Rs 25,000 for a bottle of 28 t...

Daclatasvir in combination with Sofosbuvir is indicated for the treatment of Hepatitis C genotype 3 infections, which is highly prevalent i...

Hetero is the first company in India to receive the approval for the fixed-dose combination Ledipasvir-Sofosbuvir (90mg/400mg) from DCGI.

People infected with HIV are already known to have an elevated risk for heart disease but hepatitis C can spark cardiovascular damage indep...

Drug major Roche has reduced the prices of its Hepatitis C treatment drug 'Exxura' by 65 per cent across all government institutions in Ind...

Hepatitis C virus causes chronic infection leading to cirrhosis and may cause liver cancer.

Researchers found that cancer rates in patients with the hepatitis C virus (HCV) were significantly increased compared to the non-HCV cohor...

Shares of Dr Reddy's Laboratories today settled with gains of nearly 2 per cent after the firm said it is planning to launch Hepatitis C dr...

Sofosbuvir is a medicine used for chronic Hepatitis C infection and sold globally by Gilead Sciences Inc, under its brand Sovaldi.

Drugmaker Mylan Laboratories Ltd said it has expanded its hepatitis C licensing agreement with Gilead Sciences, a US-based biopharma compan...

Approximately one-third of HIV patients in the US have hepatitis C, with an estimated 7 million co-infected patients worldwide.

The findings can bring an effective hepatitis C vaccine closer to reality.

The report said the prevalence of Hepatitis C is estimated to be within 1.8-2.5 per cent, while among drug users it is 50-90 per cent.